Melinda Becker, MD
Pulmonary Disease · Huntington, WVNPI 1508252297
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $342, 3.6 times the $96 reported in 2020. That places this record below the midpoint for pulmonary disease clinicians in WV, where the typical reported total is $1,097.
Across 32 payments — averaging $24.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$179
- Regeneron Healthcare Solutions, Inc.$159
- Inspire Medical Systems, Inc.$138
- Pulmonx Corporation$120
- GSK$89
- Philips North America LLC$30
- plus $60 from 3 others
What the payments were for
- Food & beverage$776100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $179 |
| Regeneron Healthcare Solutions, Inc. | 11 | $159 |
| Inspire Medical Systems, Inc. | 1 | $138 |
| Pulmonx Corporation | 3 | $120 |
| GSK | 5 | $89 |
| Philips North America LLC | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Boehringer Ingelheim | 1 | $16 |
| Verona Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$138
How this compares
$776 in reported general payments places this provider in the 40th percentile of 89 pulmonary disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fasenra PenBenralizumab | 26 | $139,625 |
| Spiriva RespimatTiotropium Bromide | 93 | $91,771 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 88 | $85,168 |
| TezspireTezepelumab-Ekko | 16 | $66,469 |
| Dupixent SyringeDupilumab | 12 | $45,876 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $41,508 |
| SymbicortBudesonide/Formoterol Fumarate | 91 | $29,966 |
| Advair HfaFluticasone Propion/Salmeterol | 25 | $20,535 |
| Incruse ElliptaUmeclidinium Bromide | 27 | $17,470 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 32 | $16,998 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 56 | $16,812 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 21 | $16,653 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $15,473 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 210 | $9,824 |
| Fluticasone-Salmeterol HfaFluticasone Propion/Salmeterol | 13 | $6,205 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $179 | $137,943148 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $16 | $125,422146 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $89 | $118,110140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 89 pulmonary disease providers in West Virginia.
Other pulmonary disease in Huntington
- Yousef ShweihatHuntington$6K
- Fadi AlkhankanHuntington$5K
- Julian Lopez GarciaHuntington$5K
- Sigurdur SigurdarsonHuntington$5K
- Imran KhawajaHuntington$2K
- Amro Al-AstalHuntington$1K
- Melvin SaludesGlen Dale$255K
- Roger AbrahamsMorgantown$133K
- Maria BoustaniBeckley$95K
- Ramzi HaddadinBeckley$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.